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The pharmaceutical industry has invested in cancer drug discovery
and development in recent years to an extent that vastly exceeds
the level of corporate involvement even as late as 1990. According
to the Pharmaceutical Research and Manufacturers of America
(PhRMA), the aggregate corporate investment in cancer drug
discovery can be estimated at $5 billion for the year 2000, and
more than 350 agents are under corporate sponsorship as anti-
cancer agents. This investment is predicated on the notion that
advances in biology elucidating the molecular derangements in
cancer cells will provide the basis for novel, safe and effective
agents for cancer treatment. The underlying paradigm and areas of
current focus have been reviewed comprehensively in a recent
monograph by Garrett and Workman (Garrett and Workman,
1999). We shall consider here counterpoints to and ramifications
of this paradigm to expand the discussion of what qualities mole-
cules for a new millennium of cancer treatment might possess. We
shall illustrate as case studies the exceptional instances where
current molecules under study approach this ideal, or illustrate
potential bumps in the road.
A key tenant of the assumed wisdom leading us down a new
path for cancer drug discovery and development is that molecules
with pathogenic significance in the causation of cancer will be key
targets in the useful treatment of cancer. The anti-bcr-abl directed
protein kinase antagonist STI-571, a drug molecule crafted to be a
specific kinase inhibitor, has emerged as a ‘poster child’ for this
new approach (Drucker and Lydon, 2000). STI-571 is a prototype
that hopefully can be generalized to other drug molecules in
addressing haematologic and paediatric neoplasms which utilize
translocation-related fusion proteins as a basis for their existence.
Yet, it is very unusual in adult oncology that a single target can be
tied unequivocally to a cancer’s pathogenesis. It is further unusual
in adult oncology for a cancer’s susceptibility to the therapeutic
agent to be uniquely biased, as normal human cells do not possess
anything quite like bcr-abl. While it is true that c-abl is a ubiqui-
tously expressed portion of bcr-abl, it appears to have a very
distinct set of cellular functions and a limited set of substrates in
comparison to bcr-abl. Common adult solid tumours actually
contain dozens of interacting targets which deregulate cell cycle
progression, convey cellular immortality (for example, by acti-
vating telomerase), have disabled cell death-promoting mecha-
nisms, and in the majority of lethal tumours have become
functionally enabled to induce new blood vessels, invade and
metastasize. Thus, a key feature of a hoped for ‘molecule of the
millennium’ will be the ability to address multiple deranged
targets in a way that is qualitatively different than current cyto-
toxics, whose value arises from the cellular response to the drug
rather than from the nature of the drugs’ targets.
How might these properties be ‘built-in’ to drugs of the millen-
nium? One approach, outlined by Kaelin (Kaelin, 1999), is to
define molecules which are active only in the context of the genet-
ically altered environment of the tumour cell. That is, one must
design agents whose actions address perhaps not a single target,
but rather, a molecular context for a target ‘process’. The relevant
target process for cancer treatment may depend on a number of
molecules, and the challenge will be in discerning the best way of
perturbing the process. For example, cancer cells possess damaged
cell cycle checkpoints as a key feature in tolerating and indeed
utilizing genetic plasticity to create ever more successful
neoplastic cells. It is therefore desirable to define therapeutic
molecules that act in a manner analogous to ‘synthetic lethal’
mutations, which result in non-viable organisms only in the
Millennium mini-review
Molecules for the millennium: how will they look?
New drug discovery year 2000
EA Sausville and JI Johnson
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Blvd., Suite 8000, 
Rockville, MD 20852, USA
Summary A new approach to cancer drug discovery targets molecules important in cancer pathogenesis. This approach is thought to be of
greater promise than the antiproliferative screens which discovered cytotoxic agents and dominated cancer drug discovery for 60 years.
However, one cannot lose sight of the fact that these targets exist in the cellular environment consisting of many additional influences on
target function, and that effective drug treatment will take into account drug uptake, metabolism and elimination at the level of the cell as well
as the organism. A key goal is to define for the new millennium a path to cancer drug discovery and development which accounts for the
cancer cell phenotype in its totality rather than as arising solely from single molecular targets. The US National Cancer Institute maintains a
cell-based drug discovery screen which can define a context for drug action in the milieu of more than 300 molecular targets and thousands
of gene expression patterns which have been measured in the 60 human tumour cell lines which comprise the screening panel. The
challenge of the millennium will be addressed by molecules active against defined targets but with selectivity of action occurring in the milieu
of deregulated cancer cell biology in all its aspects. © 2000 Cancer Research Campaign http://www.bjcancer.com
Keywords: drug discovery paradigm; molecular targets; anticancer therapeutics; in vitro screens
1401
Received 7 August 2000
Accepted 8 August 2000
Correspondence to: EA Sausville
British Journal of Cancer (2000) 83(11), 1401–1404
© 2000 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1473, available online at http://www.idealibrary.com on  http://www.bjcancer.comcontext of damaged checkpoint mutations. By this approach, drug
discovery screens might be devised to detect molecules active only
in cells bearing mutations in the various checkpoint-regulated
pathways. Friend, Hartwell and colleagues have devised a screen
which detects compounds (Simon et al, 2000) with differential
activity in yeast engineered to possess such checkpoint alterations,
and data emerging from this effort are available in part through
http://dtp.nci.nih.gov. As with any screen, however, these are only
‘leads’ whose relevance to mammalian tumour cell biology must
now be explored and exploited. Other types of ‘synthetic lethal’
screens might be conceived, e.g., molecules active only in the
context of an activated ‘mutation’ phenotype, or active in the
context of deregulated E2F (Kaelin, 1999).
An extension of this way of thinking is to recognize that a mole-
cular target of one type, e.g., which promotes cell cycle deregula-
tion, exists in a cancer cell in the context of other molecules
responsible for a target-directed drug’s uptake, intracellular
metabolism and elimination. An example in the most elementary
sense of this concept is afforded by 5-fluoropyrimidines. Studies
by Danenberg and colleagues have illustrated the potential impor-
tance of the level of thymidylate synthase (TS) and DNA repair
enzymes, such as ERCC1, in conveying the likelihood of clinical
responses to 5-fluorouracil (5FU) and cis-platinum-based
regimens (Metzger et al, 1998). More recently, it has likewise been
elucidated that the expression or activity of dihydropyrimidine
dehydrogenase (DPD) is a key determinant of susceptibility to
fluoropyrimidines (Salonga et al, 2000). Therefore, the real
‘target’ of 5FU is not simply TS, but the milieu created by a
particular cell type’s susceptibility to thymineless death (perhaps
governed by p53 and cell cycle checkpoint-related pathways), plus
its TS and DPD levels, not to mention the nucleoside salvage path-
ways which allow formation of FdUMP in the first place. These
studies emphasize that elucidation of novel agents to perturb target
molecules must operate in a cellular milieu, where the substrate of
the target’s action and indeed the drug molecule, are variables that
must be effectively addressed in correcting the consequences of
targeted effects.
A recently defined example where drug metabolism must be
considered in relation to the design of drugs to effect a growth
regulatory molecule is the elucidation that the action of
geldanamycins, which target hsp90-binding signal transducing
molecules (Whitesell et al, 1994; Stebbins et al, 1997) can be
influenced by expression of DT-diaphorase (Kelland et al, 1999).
It is thus possible that the real ‘target’ of geldanamycin is the rela-
tionship between ‘levels’ or activity of hsp90-related signalling
systems in relation to the consequences of diaphorase action on
geldanamycins. Elucidation of the cellular disposition of bound
drug, therefore, becomes of great importance in how to design
agents related to target action or to optimize the cellular events
effected by a drug.
These circumstances lead us to challenge the assertion that there
is little value in understanding the action of novel cytotoxic
compounds, irrespective of how exotic their point of origin may be
(Garrett and Workman, 1999). For example, the novel cytotoxic
agent, ET 743 (ecteinasceidin), causes a unique DNA lesion
(Pommier et al, 1996). Early clinical studies have suggested some
activity on the part of ET 743 in soft tissue and osteosarcomas, but
at the cost of noteworthy toxicity (Taamma et al, 1998). The
challenge to natural product and synthetic chemists is to team
with biologists to understand how to steer the unique cytotoxic
mechanism of ET 743 to where it is useful with an enhanced ther-
apeutic index. In fact, obstinately persisting in clinical develop-
ment schemes without considering the possibility of molecular
refinement could doom an otherwise potentially useful agent.
Discovery screens for molecules of the millennium must, there-
fore, be designed with much deliberation as to the cellular contexts
of targets residing in the selected tumour cells. In this regard, data-
bases of target expression as a function of cancer cell type will
be invaluable. The Cancer Genome Anatomy Project (CGAP) is
creating publicly accessible databases of differentially expressed
genes in various cell types (http://www.ncbi.nlm.nih.gov/CGAP/).
Another publicly accessible database is the NCI in vitro anti-
cancer drug screening database. The methods and operation of
this screen have recently been altered to increase capture of cell
information while improving cost-effectiveness. The drug screen
currently utilizes an in vitro prescreen consisting of three human
tumour cell lines (breast MCF7, CNS SF-268, and lung NCI-
H460) against which potential chemotherapeutic agents are tested
at a single dose for a 48-hour exposure period. Test agents which
inhibit the growth of at least one of the cell lines to 32% or less of
control cell growth are tested against a panel of 60 human tumour
cell lines over a 5-dose range of one-log dilutions. This in vitro
assay system has been described previously (Monks et al, 1991;
Paull et al, 1995; Alley et al, 1998), and the most current
information concerning this test system is catalogued on the
Developmental Therapeutics Program, NCI Web site (http://
dtp.nci.nih.gov). The NCI in vitro cell screening data can be used
as a basis for assessing initial mechanisms of action through
computational database searching. For example, COMPARE is a
pattern-recognition algorithm which compares the effect of a test
agent on the 60 cell line panel to the database of both standard
agents of known anti-proliferative mechanism, as well as that of
more than 77 000 compounds which have been evaluated in the
screen. The use of this database to discover novel associations of
drug chemotypes with molecular mechanisms has been previously
described (Monks et al, 1997).
Initial studies with the MDR-1 drug resistance protein encour-
aged the notion that profiling of the cell line panel for a target
could lead to the definition of structure activity through or in
relation to the target (Wu et al, 1992). More than 300 such single
molecular target determinations are currently either underway or
have now been carried out, mostly through highly valuable
collaborations with academia and industry, and are listed on
http://dtp.nci.nih.gov. COMPARE is utilized to determine if the
pattern of cellular sensitivity and resistance for a test compound
can be related to a measured molecular target. The molecular
target COMPARE has identified, for example, ras inhibitors (Koo
et al, 1996), DT-diaphorase correlates (Fitzsimmons et al, 1996),
and thioredoxin inhibitors (Kunkel et al, 1997). As additional
collaborations are fostered and additional targets measured,
patterns of activity from the entire database of results from the in
vitro 60 cell line panel are compared to the target database in an
effort to identify new leads for development. Data from the in vitro
screen have also been analysed with the help of DISCOVERY
(Weinstein et al, 1997), which uses a clustering algorithm to group
compounds by cellular response patterns. The clustered correla-
tion feature of DISCOVERY is used to produce a map of the rela-
tion between chemical compounds evaluated in the 60 cell line
assay and molecular targets which have been measured in the
cells.
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availability of gene expression patterns for thousands of expressed
genes through NCI’s collaboration with Brown and Botstein (Ross
et al, 2000), and Weinstein (Scherf et al, 2000). The public avail-
ability of these data through, for example, http://dtp.nci.nih.gov,
offers a way of aligning the presence of various chemotypes to
patterns of gene expression. Intrinsic ability of a given chemotype
to cause an anti-proliferative effect may be aligned with efforts
to design structures with the capacity to affect additional targets
present in the desired cell type.
Thus, a hoped for ‘molecule of the millennium’ might act to
affect an important target pathway, e.g., the ras pathway, not by
focusing on a feature such as its dependence on the promiscuously
expressed farnesyl transferase modification, but by focusing on
the essence of ‘ras-ness’, namely the ability of the drug to interact
persistently with its proliferation-promoting targets, e.g., raf or
P13-kinase. The drug molecule might have been detected by a
functional screen which defined alteration of raf-related or
P13-kinase signal output as a criterion for success. The drug will
have been further modified to promote the successful uptake or
distribution to, for example, visceral solid tumours (pancreas,
lung, colon, etc.) where the biologic data is compelling for a role
for ras in promoting malignant cell behaviour. The molecule will
have been crafted to avoid or de-emphasize facile metabolic deac-
tivation, or will have been selected to possess prolonged residence
time at the target. Appreciation of the metabolic milieu in which
the drug must function will have been gleaned by considering the
frequency and type of genes in databases such as CGAP and
related efforts.
This last point raises another issue in selecting molecules for
further optimization as cancer therapeutics. A common dictum in
the development of small molecules for non-cancer indications is
that molecules with high affinity for their particular target but
which act in a biochemically reversible mechanism should be the
goal of drug discovery paradigms. Affinity constants of nM are to
be desired. Molecules which cause covalent modification of target
proteins, e.g., Michael acceptors or molecules with ‘alkylating’
potential should be avoided. Since cancer treatments must, as
described above, operate in a cellular environment relevant to
several molecular targets to convey a persistent cytostatic or very
differentially cytotoxic effect, we must consider that some
rethinking of these precepts may be in order to address the special
case of cancer therapy-directed agents. Specifically, a very tight
binding inhibitor that is functionally irreversible or indeed cova-
lent may not be such a bad idea, provided that the binding occurs
in an appropriately specific context. The value of this approach
would then be to allow more intermittent dosing and thus a poten-
tially augmented therapeutic index. Certain conventional agents,
e.g., deoxycoformycin vs. adenosine deaminase, or investigational
agents, e.g., O6-benzyl guanine vs. alkyl-guanine alkyl transferase,
demonstrate that selectivity of action is possible even with such
molecular features. Certain protein kinase antagonists likewise are
covalent tight binding inhibitors with marked selectivity for targets
(Fry, 1999). In fact, a covalent or kinetically irreversible inter-
action with a specific target may be yet one more way of
augmenting drug selectivity to the range of targets expressed in the
cancer cell milieu.
The development of irreversible or ultra-tight binding inhibitors
also recognizes that an ultimate goal of cancer treatment for the
major fraction of afflicted patients is reduction of cell mass. As the
greatest fraction of cells of the average solid tumour may not be in
an actively proliferating phase of the cell cycle at the time of treat-
ment, such tight binding inhibitors may occupy their binding sites
and therefore be available to afford a useful therapeutic effect at
the time the cell next attempts cycle re-entry. By this view, an
additional challenge for the millennium will be discerning targets
whose efficient ligation to a small molecule will lead to a signal for
apoptosis, as a result of their structure or altered function in the
liganded state. While it could be argued that this paradigm is suspi-
ciously similar to that which underlies the action of DNA-directed
alkylating agents, we must remember that these drugs actually do
work, albeit in the minority of diseases. One would profitably
consider the characteristics which afforded these drugs their
success, and attempt to emulate their properties, but with a range
of novel targets differentially expressed in tumour cells.
A final topic area is the important role of the cancer cell micro-
environment in defining a basis for potential differential suscepti-
bility to new agents. Other authors have stressed aberrant
micro-circulation and dependence on neovascularization
ubiquitous in successful tumours (Hahnfeldt et al, 1999;
Ramanujan et al, 2000). It is still not clear how the expression of
biochemical targets in the matrix, consisting of altered, proteo-
lysed basement membrane, clotting cascade elements and
remnants, and shed cell surface antigens and receptors can be
systematically defined in primary and metastatic lesions from
various tumour types. This micro-environment could serve as a
barrier to drug penetration, or could actually be the basis for
devising strategies for novel tumour targeting properties again
‘built into’ the drug’s design. The ‘molecule of the millennium’
would be designed with the tumour micro-environment in mind
and potentially use its characteristics to advantage. This strategy
would further promote a marriage between traditional small mole-
cule drug discovery paradigms and biologically based selection
strategies such as the use of phage display to define binding motifs
with relevance to tumour matrix components.
It is clear that we are poised upon the threshold of a new age of
cancer therapeutics predicated on exploiting the differences
between normal and cancer cells. We will depend for accurate
depiction of these therapeutic opportunities on the molecules that
define successful tumours as they occur in the human host, and not
merely the ubiquitously deranged common lesions that cause the
cancer, as revealed by experiments in model systems. Design of
successful drugs must take into account aspects of a tumour cell’s
molecular contexts, metabolism and architecture. Development
schemes to emphasize ‘real time’ confirmation in pre-clinical
models as well as in early clinical trials that a drug is having the
desired effect on its intended target and delivery to target tumour
cell populations would be optimal and should be seriously
considered as adding value and not ‘frosting’ on development
plans. For molecules with an intended cytostatic effect, such
information could be key in deciding to move a molecule to initial
or more advanced (post Phase I) clinical testing. In this way 
there will be a seamless linking of the opportunities dreamed of
at a drug molecule’s initial conception with optimal development
and use.
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